美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

76.05

-0.0459-0.06%

成交量：489.00

成交額：3.72萬

市值：76.05萬

市盈率：- -

高：76.05

開：75.91

低：75.91

收：76.09

52周最高：85.03

52周最低：48.14

股本：1.00萬

流通股本：1.00萬

量比：2.19

換手率：4.89%

股息：0.79

股息率：1.04%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

跨國藥企2025年成績單：「藥王」易主，創新資產交易創新高

21世纪经济报道

跨國藥企瀕臨3000億美元專利懸崖

国际金融报

GSK收購35Pharma 獲得肺動脈高壓新藥；全球首款血友病基因療法退市 | 醫藥早參

每日经济新闻

葛蘭素史克將以9.5億美元收購生物技術公司35Pharma

葛蘭素史克(GSK.US)9.5億美元收購35 Pharma，發力心血管藥物賽道

超10億美元！前沿生物牽手GSK 小核酸賽道再升温

21世纪经济报道

股海導航_2026年2月24日_滬深股市公告與交易提示

四大證券報頭版頭條內容精華摘要_2026年2月24日_財經新聞

和鉑醫藥宣佈新一代CTLA-4抗體授權交易；前沿生物與葛蘭素史克簽署授權許可協議 | 醫藥早參

每日经济新闻

前沿生物(688221.SH)與葛蘭素史克簽署授權許可協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GSKH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":76.0458,"timestamp":1773691200000,"preClose":76.09168,"halted":0,"volume":489,"delay":0,"changeRate":-0.000602956854152738,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"已收盤","change":-0.04588,"latestTime":"03-16 16:00:00 EDT","open":75.91,"high":76.0458,"low":75.91,"amount":37150.4265,"amplitude":0.001785,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1773734400000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":76.09168,"nav":76.884151,"aum":768918.394151,"dividendRate":0.010356,"bidAskSpread":0,"volumeRatio":2.186942},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.186942,"shares":10001,"dividePrice":0.7875,"high":76.0458,"amplitude":0.001785,"preClose":76.09168,"low":75.91,"week52Low":48.14,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":76.0458,"eps":0,"divideRate":0.010356,"volume":489,"delay":0,"ttmEps":0,"open":75.91,"prevYearClose":68.2031,"prevWeekClose":76.455,"prevMonthClose":82.5898,"prevQuarterClose":68.2031,"fiveDayClose":78.0867,"twentyDayClose":80.7182,"sixtyDayClose":68.2433},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618933958","title":"跨國藥企2025年成績單：「藥王」易主，創新資產交易創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618933958?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","LU1934455863.HKD","LU1093756325.SGD","CDE","LU2361045086.USD","SG9999015358.SGD","IE00BJJMRZ35.SGD","LU2360032135.SGD","GSKH","MRK","BK4588","LU0477156953.USD","SGXZ57979304.SGD","BK4534","LU1983299246.USD","NVOX","LU0130517989.USD","LU0648001328.SGD","LU2125154778.USD","LU2324357040.USD","GSK.UK","IE00B1BXHZ80.USD","LU0320765489.SGD","LU1066051811.HKD","LU0203347892.USD","LU0868494617.USD","IE00BKVL7J92.USD","LU1223082519.USD","LU1989772840.SGD","BK4559","BK4550","BK4585","LU1023059063.AUD","LU2361044865.SGD","LU1291159041.SGD","SG9999014575.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU1571399168.USD","LU0289739699.SGD","BK4516","LU0098860793.USD","GSK","LU1066051225.USD","LU0266013472.USD","SG9999001176.USD","SG9999014542.SGD","01477","LU1057294990.SGD","NVOH"],"gpt_icon":1},{"id":"2614889372","title":"跨國藥企瀕臨3000億美元專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2614889372","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614889372?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 07:50","pubTimestamp":1772236210,"startTime":"0","endTime":"0","summary":"近期，强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中，强生以942亿美元总营收位居首位，罗氏凭借五大重磅药物获得744.3亿美元收入，位居第二；得益于替尔泊肽双靶点减肥药，礼来以651.79亿美元挤进前三，成为2025年业绩榜最大黑马。总体看，大部分跨国药企业绩实现了稳定增长，部分明星药品对业绩影响较大。业内人士认为，专利悬崖冲击将是巨头们接下来要面临的核心压力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657287047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657287047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2125154935.USD","LU1496350502.SGD","LU1196500208.SGD","LU1244550577.SGD","SG9999013999.USD","LU0203347892.USD","LU2750360997.AUD","LU0985320562.USD","IE0034235303.USD","PFE","LU0345769128.USD","LU1674673428.USD","LU2602419157.SGD","IE00BVYPNW00.USD","LU0980610538.SGD","IE00B7SZLL34.SGD","LU1989772840.SGD","LU0321505439.SGD","LU2023250504.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1093756168.USD","LU2750360641.GBP","LU1244550221.USD","LU1935042991.SGD","LU1032466523.USD","BK4516","LU0289739699.SGD","LU0203345920.USD","LU1989771016.USD","LU1280957306.USD","LU2112291526.USD","LU2471134952.CNY","SG9999003800.SGD","IE00B19Z3581.USD","LU1074936037.SGD","LU0320765646.SGD","LU2125154778.USD","LU0208291251.USD","LU1069347547.HKD","LU1267930813.SGD","IE0009355771.USD","BK4187","LU0795875086.SGD","LU0106261372.USD","IE000M9KFDE8.USD","LU1037948541.HKD","SG9999002224.SGD","BK4533","LU0265550946.USD","IE00BDGV0183.EUR","IE00BVYPNV92.GBP","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0130102774.USD","BK4588","BK4599","LU0912757837.SGD","LU0238689110.USD","IE00BBT3K403.USD","LU0985481810.HKD","LU2461242641.AUD","BK4585","LU0965508806.USD","SG9999014559.SGD","IE00B1BXHZ80.USD","LU1093756325.SGD","LU1894683264.USD","LU0456855351.SGD","LU0477156953.USD","LU0965509101.SGD","LU1057294990.SGD","LU2471134796.USD","LU2023250843.SGD","LU0306806265.USD","LLY","LU1162221912.USD","IE00BGHQF631.EUR","LU0124676726.USD","LU1917777945.USD","IE0002270589.USD","LU1066051498.USD","SG9999015358.SGD","LU1059921491.USD","LU2089984988.USD","SG9999015341.SGD","IE00B3PB1722.GBP","LU1941712264.USD","LU1829250122.USD","LU1201861249.SGD","IE0001KFT4U8.USD","LU1934455863.HKD","LU2133065610.SGD","LU2505996509.AUD","IE0002141913.USD","LU2324357040.USD","LU2129689605.HKD","GSKH","LU0861579265.USD","LU2471134879.HKD","LU2106854487.HKD","LU0070217475.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU1732800096.USD","LU1929549753.HKD","SG9999001440.SGD","SG9999014567.USD","LU0006306889.USD","LU2430703095.HKD","IE00BLSP4239.USD","BK4077","LU0466842654.USD","IE00BN8TJ469.HKD","LU1699723380.USD","LU1037948897.HKD","LU0792757196.USD","LU1221951129.SGD","IE00B19Z3B42.SGD","LU2430703251.USD","LU0130517989.USD","BK4504","NVO","LU2361045086.USD","LU1066053197.SGD","LU1291159041.SGD","LU2129689431.USD","LU1506573853.SGD","LU1116320737.USD","BK4532","LU0321505868.SGD","LU1718418525.SGD","LU2592432038.USD","LU0234572021.USD","SG9999011175.SGD","LU0965509010.AUD","LU1244550494.USD","LU0320765489.SGD","LU0965509283.SGD","LU1061106388.HKD","LU1989772923.USD","LU0170899867.USD","LU2129689514.USD","LU0211331839.USD","LU2430703178.SGD","LU2505996681.GBP","BK4568","LU0787776722.HKD","SG9999002232.USD","IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","LU0345770993.USD","LU1974910355.USD","SG9999001176.USD","LU0868494617.USD","LU2347655156.SGD","SGXZ57979304.SGD","LU1066051225.USD","BK4581","LU0648001328.SGD","IE00BFXG1179.USD","LU0070302665.USD","LU0114720955.EUR","SG9999001176.SGD","LU1983299246.USD","GSK.UK","LU0432979614.USD","LU1883839398.USD","LU1934455194.USD","LU0098860793.USD","LU0225284248.USD","LU1430594728.SGD","BK4592","LU0345770308.USD","LU2361044865.SGD","LU1674673691.USD","GSK","IE00B3T34201.USD","LU0265550359.USD","LU0683600562.USD","JNJ","LU1778281490.HKD","SNY","LU0640476718.USD","BK4559","LU0234570918.USD","LU0795875169.SGD","NVS","LU1934455277.USD","BK4534","LU1732799900.SGD","IE00B42XCP33.USD","LU1571399168.USD","BK4007","LU0122379950.USD","LU0882574055.USD","LU0266013472.USD","MRK","IE00BZ1G4Q59.USD","LU1585245621.USD","LU2360032135.SGD","AZN","LU1032955483.USD","LU1894683348.USD","RHHBY","IE00BSNM7G36.USD","LU0306807586.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU1914381329.SGD","LU2468319806.SGD","LU1116320901.HKD","LU1941712348.USD","SG9999014542.SGD","BK4550","SG9999014575.USD","LU0058720904.USD","LU0345769631.USD","LU0689626769.HKD","LU0889566641.SGD","LU1261432733.SGD","LU1035773651.USD","LU2471134523.USD","LU1221951046.USD","LU1066051811.HKD"],"gpt_icon":1},{"id":"2614450050","title":"GSK收購35Pharma 獲得肺動脈高壓新藥；全球首款血友病基因療法退市 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2614450050","media":"每日经济新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614450050?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 07:06","pubTimestamp":1772060804,"startTime":"0","endTime":"0","summary":"丨2026年2月26日星期四丨NO.1先声药业2025年归母净利润预增80.1%至93.9%2月25日，先声药业发布盈利预告，公司2025财政年度将录得收入约人民币77亿元至78亿元，同比增长约16.0%至17.6%；将录得归属于本公司权益股东的利润约人民币13亿元至14亿元，同比增长约80.1%至93.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263654473544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263654473544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4532","GSK","BK1161","BK4585","BK4588","159938","GSKH","BK1515","09939","LU1829250122.USD","BK1574","GSK.UK"],"gpt_icon":0},{"id":"2614217087","title":"葛蘭素史克將以9.5億美元收購生物技術公司35Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2614217087","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614217087?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 21:28","pubTimestamp":1772026083,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","LU1829250122.USD","BK4007","GSK.UK","BK4585","GSK","BK4588","GSKH"],"gpt_icon":0},{"id":"2614701423","title":"葛蘭素史克(GSK.US)9.5億美元收購35 Pharma，發力心血管藥物賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614701423","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614701423?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 16:45","pubTimestamp":1772009150,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克已同意收购 35Pharma Inc.，这是一家拥有早期高血压药物资产的生物技术公司。此举标志着这家英国制药巨头正向心血管药物领域扩张。葛兰素史克在周三的一份声明中表示，将以 9.5 亿美元现金收购这家私人持有的加拿大公司。葛兰素史克目前最大的财务压力来自于其支柱性 HIV 药物将在 2028 年前后遭遇专利到期。1月20日，葛兰素史克还宣布收购美国上市药企RAPT Therapeutics。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克(GSK.US)9.5亿美元收购35 Pharma，发力心血管药物赛道","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","GSK","GSKH","LU1829250122.USD","BK4585","BK4588","GSK.UK","BK4007"],"gpt_icon":0},{"id":"2613764331","title":"超10億美元！前沿生物牽手GSK 小核酸賽道再升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2613764331","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613764331?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 14:08","pubTimestamp":1771913295,"startTime":"0","endTime":"0","summary":"小核酸领域再迎重磅BD（商务拓展）交易。2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652625697.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652625697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","688221","GSK","GSKH","BK4532","BK0239","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2613975138","title":"股海導航_2026年2月24日_滬深股市公告與交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975138","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613975138?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 08:30","pubTimestamp":1771893000,"startTime":"0","endTime":"0","summary":"经初步测算，预计本次方案将对公司2026年度归母净利润产生一定负面影响，影响金额低于公司2024年度经审计归母净利润的5%，不会对公司整体业务发展产生实质性影响。　　ST京蓝公告，自2026年1月23日至2026年2月13日期间公司股票价格涨幅为86.90%，短期内价格涨幅较大，公司业绩未发生重大变化，但近期公司股票价格严重脱离公司业绩情况，投资者参与交易可能面临较大风险，如未来公司股票价格进一步异常上涨，公司可能申请停牌核查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-02-24/doc-inhnwmhy3272551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","GSK.UK","LU1829250122.USD","IND","GSK","BK4532","BK4007","BK4585","GSKH"],"gpt_icon":0},{"id":"2613751897","title":"四大證券報頭版頭條內容精華摘要_2026年2月24日_財經新聞","url":"https://stock-news.laohu8.com/highlight/detail?id=2613751897","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613751897?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 08:29","pubTimestamp":1771892940,"startTime":"0","endTime":"0","summary":"　　2月24日（星期二），今日报刊头条主要内容精华如下：。中方敦促美方取消对贸易伙伴加征的有关单边关税措施。　　2月23日晚，国投瑞银基金发布公告称，近期国投白银LOF二级市场交易价格出现较大幅度溢价。　　截至2月23日18时，2026年春节档电影总票房已突破56亿元，总场次刷新中国影史春节档最高纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/y/2026-02-24/doc-inhnwmhw6169991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4532","BK4007","GSKH","GSK.UK","SImain","BK4588","BK4585","LU1829250122.USD","GSK"],"gpt_icon":0},{"id":"2613133755","title":"和鉑醫藥宣佈新一代CTLA-4抗體授權交易；前沿生物與葛蘭素史克簽署授權許可協議 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2613133755","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613133755?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 07:02","pubTimestamp":1771887756,"startTime":"0","endTime":"0","summary":"丨2026年2月24日星期二丨NO.1和铂医药就新一代CTLA-4抗体达成授权协议及股权合作2月23日，和铂医药公告称，公司与SOLSTICEONCOLOGY就HBM4003订立授权协议及股权合作协议。据此，公司同意向SolsticeOncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652107028.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652107028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4007","BK4585","GSKH","BK1161","BK4532","BK1574","BK0239","BK1583","LU1829250122.USD","GSK","02142","BK4588","159938","688221","09939","GSK.UK"],"gpt_icon":0},{"id":"2613788810","title":"前沿生物(688221.SH)與葛蘭素史克簽署授權許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2613788810","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613788810?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:57","pubTimestamp":1771837051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，前沿生物 发布公告，公司与全球生物制药企业葛兰素史克达成一项独家授权许可协议。葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报及商业化活动。本次与全球领先的生物制药企业GSK达成此项协议，体现了公司在小核酸药物研发领域的技术实力与平台价值正获得国际市场认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688221","BK0239","BK4532","BK4585","BK4588","BK4007","GSK.UK","LU1829250122.USD","GSK","GSKH"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}